683 Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

683 Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500,000	Closed	-$4.36M	–	282
2023 Q1	$4.36M	Sell	500,000 -700,000	-58%	-$5.6M	0.32%	81
2022 Q4	$7.52M	Sell	1,200,000 -270,000	-18%	-$1.03M	0.64%	43
2022 Q3	$5.14M	Hold	1,470,000	–	–	0.4%	63
2022 Q2	$4.34M	Buy	1,470,000 +370,000	+34%	+$884K	0.31%	78
2022 Q1	$3.42M	Hold	1,100,000	–	–	0.18%	98
2021 Q4	$3.72M	Buy	+1,100,000	New	+$4.18M	0.14%	101

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

683 Capital Management's CBAY Position: Q2 2023 in Review

683 Capital Management sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 500,000 shares — an estimated $4.36M sold.

683 Capital Management first reported a position in CBAY in Q4 2021 and held it in 6 quarters. The position peaked at $7.52M in Q4 2022. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

683 Capital Management reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
683 Capital Management sold 500,000 Cymabay Therapeutics shares in Q2 2023, an estimated $4.36M.
683 Capital Management first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 6 quarters.
683 Capital Management's Cymabay Therapeutics position peaked at $7.52M in Q4 2022.
151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.